GlobalData’s report assesses the drugs in the Hepcidin pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.
Image Source: Zacks Investment Research Incyte’s lead drug, Jakafi, is a JAK1/JAK2 inhibitor approved for the treatment of polycythemia vera (PV) in adults who have had an inadequate response to ...
Ropeginterferon alfa-2b (Ropeg) is approved for the treatment of adults with polycythemia vera (PV). This report aims to analyze the ethnic sensitivity of Ropeg for the treatment of PV, comparing the ...